UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Molecular cancer, ISSN 1476-4598, 12/2015, Volume 14, Issue 1, pp. 207 - 207
DLBCL | ABC-DLBCL | DTX3L | STAT1 | CAR-T cells | Chemoresistance | STAT3 | PARP | GCB-DLBCL | Antibody drug conjugate | BCR | NF-ΚB | Macrodomain | ADP-ribosylation | ARTD | Biochemistry & Molecular Biology | Oncology | Life Sciences & Biomedicine | Science & Technology | Animals | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Immunotherapy | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Precision Medicine | Phosphates | Ubiquitin | Biological products | Genes | Mortality | Development and progression | Non-Hodgkin's lymphomas | B cells | Transforming growth factors | Gene expression | T cells | Chemotherapy | Ligases | Health aspects | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 11/2011, Volume 117, Issue 22, pp. 5058 - 5066
nongerminal center B‐cell–like lymphoma | relapsed/refractory | lenalidomide | Hans algorithm | diffuse large B‐cell lymphoma | germinal center B‐cell–like lymphoma | germinal center B-cell-like lymphoma | diffuse large B-cell lymphoma | nongerminal center B-cell-like lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Recurrence | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prognosis | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Germinal Center - pathology | Thalidomide - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Lymphoma, Large B-Cell, Diffuse - classification | Female | Aged | Thalidomide - therapeutic use | Care and treatment | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
3.
Full Text
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
The Journal of clinical investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3351 - 3362
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Neoplasm Transplantation | Proto-Oncogene Proteins c-bcl-6 - antagonists & inhibitors | Translocation, Genetic | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Magnetic Resonance Spectroscopy | Humans | Gene Expression Regulation, Neoplastic | Male | Mice, SCID | Animals | Proto-Oncogene Proteins c-bcl-6 - metabolism | Drug Design | HEK293 Cells | Cell Line, Tumor | Protein Binding | Indoles - pharmacology | Ligands | Antineoplastic Agents - pharmacology | Mice | Thiazolidinediones - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Physiological aspects | Care and treatment | Usage | Lymphomas | Enzyme inhibitors | B cells | Index Medicus | Abridged Index Medicus
Journal Article